NCT01366287View on ClinicalTrials.gov

A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

PF-03882845

25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition

DRUG

PF-03882845

25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition

DRUG

PF-03882845

25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition

Trial Locations (1)

1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY